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Antibodies against the Human papillomavirus 16 (HPV16) E6 oncoprotein appear years prior to clinical
diagnosis of anal and oropharyngeal cancer, but whether they develop around the time of HPV infection
is unclear. Serum samples from 173 cancer-free men from the Human Papillomavirus Infection in Men
(HIM) Study were tested for HPV antibodies and DNA. HPV16 E6 seropositivity was low among men with
oral HPV16-infection (1/28; 3.6%, 95%CI¼0.0–18.4%), anal HPV16-infection (1/61; 1.6%, 95%CI¼0.0–8.8%),
and 24-month persistent genital HPV16-infection (1/84; 1.2%, 0.0–6.5%). This suggests E6 seroconversion
may not occur around the time of oral, anal, or genital HPV16 acquisition.
& 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Overexpression of the E6 and E7 oncoproteins are believed to
drive the transition from benign human papillomavirus (HPV) in-
fection to carcinogenesis, as E6/E7 overexpression has been ob-
served in HPV-driven cancers, including cervical, penile, anal, and
oropharyngeal cancer [1]. Recent reports found that seropositivity
against the HPV16 E6 oncoprotein has a high sensitivity and spe-
ciﬁcity for HPV16-driven oropharyngeal and anal cancer[2–4] and
is often detected in pre-diagnostic serum among individuals with
these cancers [5,6]. These analyses suggest that while HPV16 E6
seropositivity may not be commonly present prior to cervical or
penile cancer [6], it is often induced within ﬁve years prior to anal
cancer [6] and ten or more years prior to oropharyngeal cancer [5].
Despite the detection of these antibodies years prior to anal
and oropharyngeal cancer, it is unclear at what point during the
natural history of HPV16, E6 seropositivity is induced by infection
at these different anatomic sites. So far, this biomarker has notB.V. This is an open access article u
iology Branch, Division of
al Center Drive, RM 6-E220,
chler).been examined in the earliest stages of the disease process (i.e.
when HPV infections are acquired). E6 seropositivity at the time of
oral HPV16 infection is of particular interest, as the oropharynx is
comprised of lymphoid tissue that may be more likely to induce
early antibody responses to infection. We therefore examined the
presence of HPV16 E6 antibodies among cancer-free individuals
with genital, anal, or oral HPV16 infection in the Human papillo-
mavirus Infection in Men (HIM) Study.2. Material and methods
2.1. Study population and design
This study is nested within the ongoing HIM Study, a semi-
annual prospective cohort of individuals recruited from Brazil,
Mexico, and the United States starting in 2005 [7]. The HIM Study
includes 4123 men aged 18–70 years who reported no prior di-
agnosis of penile or anal cancer, had never been diagnosed with
genital warts, and reported no treatment or symptoms of a sexu-
ally transmitted infection. All consenting participants had genital,
anal, and serum samples collected at semi-annual HIM Study
visits, and have been followed for a median of four years. Oral
rinse and gargle sample collection was initiated in 2007 for allnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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DNA from 1626 HIM men who reported no history of head and
neck cancer and provided oral samples on two or more semi-an-
nual study visits [8,9]. All HIM participants gave written informed
consent, and the Human Subject Committees of the University of
South Florida (Tampa, FL), Ludwig Institute for Cancer Research
(São Paulo, Brazil), Centro de Refêrencia e Treinamento em
Doencas Sexualmente Transmissiveis e AIDS (São Paulo, Brazil),
and Instituto Nacional de Salud Pública de Mexico (Cuernavaca,
Mexico) approved all study procedures.
For this study, we selected 173 individuals with the putative
highest likelihood of HPV16 E6 seropositivity. This included all
individuals who had a detectable oral or anal HPV16 infection
during the HIM Study and individuals who had a genital HPV16
infection that persisted for at least 24 months. We restricted to
these individuals given the very low prevalence of E6 ser-
opositivity in the general population [2]. While oral and anal
samples have been collected on most HIM participants, HPV DNA
testing has only been performed on a subset and thus there were
fewer men with known anal and oral infections. As such, the study
included 28 individuals with an oral HPV16 infection [8], 61 with
an anal HPV16 infection, and 84 individuals with 24-month per-
sistent genital HPV16 infection.
For the 28 oral HPV16 infected individuals, we selected the
serum sample corresponding to the visit when oral HPV16 DNA
was last detected, as well as two other serum samples collected
one and two years after that visit. For participants that were oral
HPV16 DNA-positive during their last HIM Study visit, a serum
sample was utilized from the last visit as well as a serum sample
collected one year prior to the last visit. Sampling was similar for
those who were anal HPV16 infected or had a 24-month persistent
genital HPV16 infection, except that only two serum samples were
tested for all of these men.
2.2. Laboratory and statistical analyses
Oral, anal, and genital sampling methods for the HIM Study
have been described previously [7,9,10]. HPV DNA was extracted
using the Qiagen QIAamp Media MDx kit according to the manu-
facturer's instructions. Samples were tested for DNA of 37 alpha
HPV types, including HPV16, using the Roche Linear Array with
PGMY09/11 PCR primers. A prevalent HPV16 infection was deﬁned
as detection at the ﬁrst tested visit, while an incident HPV16 in-
fection was deﬁned as being ﬁrst detected after having at least one
negative test at a prior visit.
Serum samples from the HIM Study were shipped on dry ice to
the German Cancer Research Center (Heidelberg, Germany) and
stored at 20 °C until analysis. Serologic testing was performed
using multiplex assays [11] by laboratory staff blinded to the oral/
anal/genital HPV16 status of the participants. Antigens were afﬁ-
nity-puriﬁed, bacterially expressed fusion proteins with N-term-
inal glutathione S-transferase. Samples were analyzed for anti-
bodies to the early oncoproteins E6 and E7, as well as the major
capsid protein (L1), and other early proteins (E1, E2, E4) of HPV16.
We used the same median ﬂuorescence intensity (MFI) cutoffs for
L1, E1, E2, E4, and E7 seropositivity as in our previous analyses
among cancer patients [2,5]. For E6 seropositivity, we utilized both
the initial cutoff of 4484 MFI and the recently employed more
stringent cutoff of 41000 MFI [2,5].
A subset of samples from this study was randomly chosen and
included as blinded duplicates. Quality control of this assay has
been previously described [12], and the intra-individual correla-
tion coefﬁcient for E6 seropositive duplicates in this study was
1.00. The three groups (oral HPV16-infected, anal HPV16-infected,
and 24-month persistent genital HPV16-infected men) were
compared through chi-square, Fisher's exact, or Wilcoxon-Mann-Whitney tests when appropriate. HPV16 E6 seropositivity pre-
valence and binomial 95% conﬁdence intervals (95%CIs) were
calculated for each risk group.3. Results
The mean age of the 173 HPV16-infected men was 35 years
(IQR¼27–42), approximately 51% were white, 16% had ever had
sex with a man, and the median lifetime number of sexual part-
ners was 15 (IQR¼8–31). Oral, anal, and genital HPV16-infected
men were similar to each other with regard to most characteristics
examined (Table 1), except anal HPV16-infected men were more
likely to be younger and to have ever had sex with a man (p-
valueso0.05).
Among the three groups, 1 of the 28 (3.6%, 95%CI¼0.0–18.4%)
oral HPV16-infected men, 1 of the 61 (1.6%, 95%CI¼0.0–8.8%) anal
HPV16-infected men, and 1 of the 84 (1.2%, 95%CI¼0.0–6.5%) men
with 24-month persistent HPV16 genital infection was HPV16 E6
seropositive (Table 2). HPV16 E6 seroprevalence was similarly low
across these three groups (p¼0.70), and all 34 men with incident
oral or anal HPV16 infection were E6 seronegative (Table 2). All
three E6 seropositive men had MFIs above the stricter deﬁnition of
positivity (MFI41000). No other men had MFIs between 484–
1000. In comparison, seroprevalences of HPV16 L1 and E4 were
signiﬁcantly higher than HPV16 E6 seroprevalence (12.7% & 13.3%
vs. 1.2%, respectively; p-valueso0.05), while the seroprevalences
of HPV16 E2 and E7 were non-signiﬁcantly higher than HPV16 E6
seroprevalence (4.0% & 6.4% vs. 1.2%, p-values40.05). The ser-
oprevalence of HPV16 L1 was 10.7% (95%CI¼2.3–28.2%) among
oral HPV16-infected men, 16.4% (95%CI¼8.2–28.1%) among anal
HPV16-infected men, and 10.7% (95%CI¼5.0–19.4%) among men
with 24-month persistent HPV16 genital infection.
The HPV16 E6 seropositive man who was oral HPV16-infected
had a prevalent oral infection at baseline that persisted through-
out the study. His E6 seropositivity was detectable at the ﬁrst visit
and persisted throughout the following two yearly visits (Online-
only Table 1). This participant was also HPV16 L1 and E2 ser-
opositive, but negative for the other HPV16 proteins tested and for
genital and anal HPV16 at each visit. The HPV16 E6 seropositive
man with an anal HPV16 infection also had a prevalent anal in-
fection at baseline, although his anal HPV16 infection cleared by
the following one year visit, and his E6 MFI declined from 1724 to
816. He was HPV16 E7 seropositive, but negative for the other
HPV16 proteins, and for oral and genital HPV16 infection. The
HPV16 E6 seropositive man who had a 24-month persistent gen-
ital HPV16 infection had an incident genital infection that
persisted 43 years, with the antibody detected 3.5 years follow-
ing HPV acquisition. His MFI increased from 962 to 1150 during his
last two annual visits (Online-only Table 1). He was also L1 ser-
opositive, but negative for the other HPV16 early proteins and for
oral and anal HPV16.4. Discussion
In this study of early HPV infection events, HPV16 E6 ser-
opositivity was rare among cancer-free individuals with genital,
anal, or oral HPV16 infection. None of the participants with in-
cident oral or anal HPV16 were E6 seropositive at the visit their
HPV infection was ﬁrst detected. Only two of 55 men with pre-
valent oral or anal HPV16 infection were E6 seropositive, and only
one man with a long-term genital HPV 16 infection was E6 ser-
opositive. This suggests it may require long-term persistence of an
oral/anal HPV16 infection or further progression to induce E6
seropositivity, or that seroconversion only occurs in a small subset
Table 1
Characteristics of the 173 HIM participants with oral, anal, or 24-month persistent
genital HPV16 infection.
Baseline characteristics of se-
lected HIM's participants
Oral HPV16
positive
Anal HPV16
positive
Genital HPV16
(24þ mo.)
positive
N¼28 N¼61 N¼84
Type of HPV16 Infection
Prevalent 11 (39%) 44 (72%) 52 (62%)
Incident 17 (61%)# 17 (28%) 32 (38%)
Age, median (IQR) 38 (28–44) 29 (25–40)^ 34 (29–43)
Younger than 30 7 (25%) 31 (51%)^ 23 (27%)
30–39 9 (32%) 13 (21%) 34 (40%)
40 or older 12 (43%) 17 (28%) 27 (32%)
Country
United States 12 (43%) 26 (43%) 29 (35%)
Brazil 8 (29%) 17 (28%) 31 (37%)
Mexico 8 (29%) 18 (29%) 24 (29%)
Race/Ethnicity
White 15 (54%) 32 (52%) 42 (50%)
Black 4 (14%) 8 (13%) 17 (20%)
Mixed 7 (25%) 19 (31%) 19 (23%)
Other 2 (7%) 2 (3%) 5 (6%)
Refused 0 (0%) 0 (0%) 1 (1%)
Cigarette Smoker
Current 5 (18%) 20 (33%) 23 (27%)
Former 6 (21%) 10 (16%) 10 (12%)
Never 17 (61%) 31 (51%) 51 (61%)
Sexual Orientationa
Men who have sex with wo-
men (MSW)
26 (93%) 42 (68%) 78 (93%)
Men who have sex with men
and women (MSMW)
1 (4%) 11 (18%)^ 3 (4%)
Men who have sex with men
(MSM)
1 (4%) 8 (13%)^ 3 (4%)
Oral sex in last six months
No 5 (18%) 8 (13%) 18 (21%)
Yes 22 (79%) 7 (11%) 63 (75%)
Not reported 1 (4%) 46 (75%) 3 (4%)
Lifetime number of sex
partners (maleþfemale),
median(IQR)
18 (10–40) 13 (6–29) 19 (10–35)
0–5 2 (7%) 11 (18%) 3 (4%)
6–20 11 (39%) 26 (43%) 34 (40%)
21 or more 9 (32%) 18 (30%) 31 (37%)
Not reported 6 (21%) 6 (10%) 16 (19%)
HIV-infection
No 28 (100%) 59 (97%) 83 (99%)
Yes 0 (0%) 0 (0%) 1 (1%)
Not reported 0 (0%) 2 (3%) 0 (0%)
# Oral HPV16 infections were more likely to be incident than the anal HPV16
(p¼0.003) or persistent genital HPV16 infections (p¼0.02).
^ Anal HPV16-infected menwere more likely to be younger and to have ever had
sex with a man than men with oral HPV16 infections or 24-month genital HPV16
infections (p-valueso0.05).
a Sexual orientation deﬁned by self-report lifetime sexual behavior data,
MSMW report having at least one lifetime female and at least one male sex partner
and MSM only reported having at least one lifetime male sex partner.
Table 2
E6 antibody status among individuals who were oral, anal, or genital HPV16 DNA
positive during the HIM study.
HPV16 status E6 positivea Total % E6
positive
95% CI
Oral HPV16 positive 1 28 3.6% 0.0–18.4%
Incident oral HPV16 infection 0 17 0.0% 0.0–19.5%
Anal HPV16 positive 1 61 1.6% 0.0–8.8%
Incident anal HPV16 infection 0 17 0.0% 0.0–19.5%
Genital HPV16 positive (2þ year
persistent)
1 84 1.2% 0.0–6.5%
Incident 2þ year pers. genital
HPV16 inf.
1 32 3.1% 0.0–16.2%
a E6 seropositivity evident at all three visits for the oral HPV16 infected man
(MFI: 3498, 5414, 3466), but only at one visit for the anal HPV16 infected man and
the genital HPV16 infected man.
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Among women, seroconversion to the HPV16 L1 capsid protein
occurs soon after cervical HPV16 infection acquisition [13], how-
ever, E6/E7 seroconversion does not occur until much later in the
disease process [6]. Less is known about oral and anal HPV natural
history, but initial nested case-control studies suggest that HPV16
E6 seroconversion may occur earlier in the natural history of oral
or anal HPV16 infection than for genital HPV16 infection [5,6].
HPV16 E6 seropositivity of oral HPV16-infected individuals is of
particular interest, given that E6 antibodies are often present at
least ten years prior to oropharyngeal cancer diagnosis [5], sug-
gesting that HPV infection of the lymphatic tissue of theoropharynx may be suited to induce an earlier humoral response
to infection compared to other anatomic sites. While it is unclear
exactly when in the infection/disease process HPV16 E6 antibodies
are induced, the results of this current study may suggest that
HPV16 E6 seroconversion does not occur immediately following
acquisition of oral (or anal and genital) HPV16 infection. Alter-
natively, E6 seroconversion may occur soon after HPV16 infection,
but preferentially among individuals pre-destined to develop or-
opharyngeal or anal cancer. Further follow-up is necessary to
distinguish between these two theories.
Oral HPV16 infection is relatively uncommon in the US, with an
overall prevalence of 1.6% in US men [14]. Initial studies have
suggested that the clearance of HPV infections may differ by
anatomic site [8,15], but many of these infections at each anatomic
site appear to clear (or become undetectable) within two years
[9,15,16]. Given this clearance and the modest incidence of or-
opharyngeal cancer (4 per 100,000 person-years) [17], rapid E6
seroconversion after oral HPV16 acquisition would have suggested
that this biomarker has a poor speciﬁcity for subsequent or-
opharyngeal cancer/pre-cancer. Instead, this study is consistent
with recent ﬁndings that HPV16 E6 seropositivity is rare among
individuals without a diagnosed cancer (0.3% in 44000 in-
dividuals with unknown HPV status, representing a speciﬁcity of
over 99%) [2]. This is consistent with the notion that HPV16 E6
seropositivity in healthy individuals may have a high speciﬁcity for
subsequent oropharyngeal cancer/pre-cancer [2]. However, further
study is needed to determine this biomarker's sensitivity, speciﬁ-
city, and positive predictive value for oropharyngeal and other
HPV-driven cancers.
While this is one of the ﬁrst studies to examine whether HPV16
E6 seropositivity is evident among individuals with HPV at several
anatomic sites using a well validated assay [11,12], there were
limitations. There were limited number of oral HPV16 infections,
and DNA at these different sites may sometimes represent de-
position rather than true infection that is required to develop a
serologic response. Larger studies are necessary to better assess
the interaction of HPV infections and E6 seropositivity. We also
lacked anal and oral HPV DNA testing on many of the participants
including some men who had 24 month persistent genital HPV16
infection. In addition, cancer history was self-reported, so it is
possible that some participants could have had undiagnosed HPV-
driven cancer.5. Conclusions
Results from this study suggest E6 seroconversion does not
occur around the time of oral, anal, or genital HPV16 acquisition in
most HPV16 infected individuals. Further research is needed to
D.C. Beachler et al. / Papillomavirus Research 2 (2016) 141–144144understand how long HPV16 needs to persist or progress at each
anatomic site to increase the likelihood of HPV16 E6 antibody
production.Funding
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